Physician profile
David B Nash
NPI 1447278536
$96,529.22
in general payments reported to CMS, 2019-2025
9 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,303 · 2020: $12K · 2021: $30K · 2022: $30K · 2023: $19K · 2024: $2,500 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $1,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,264.80 |
| Travel and Lodging | $1,963.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $58,997.48 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13,723.58 | 2023 | |
| Optinose US, INC. | $9,000.00 | 2020 | |
| Glaxosmithkline, LLC. | $6,420.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $4,770.00 | 2020-2021 | |
| Novo Nordisk INC | $2,019.73 | 2019 | |
| Talis Biomedical Corporation | $1,250.00 | 2022 | |
| Novo Nordisk Health Care Ag | $282.88 | 2019 | |
| Cook Medical LLC | $65.55 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.